Hongbo Xie

Mr. Hongbo Xie

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Drug Discovery Today
Verified
Journal Article
Closed access
JYJingbo Yang
Jingbo Yang
YCYiyang Cai
Yiyang Cai
KZKairui Zhao
Kairui Zhao
HXHongbo Xie
Hongbo Xie
Xiujie ChenXiujie Chen
Xiujie Chen

4 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
HXHongbo Xie
Hongbo Xie
HWHaixia Wen
Haixia Wen
DZDenan Zhang
Denan Zhang
LLLei Liu
Lei Liu
BLBo Liu
Bo Liu
Xiujie ChenXiujie Chen
Xiujie Chen
Designing of dual inhibitors for GSK-3 and CDK5: Virtual screening and in vitro biological activities study

5 October 2016 in RSC Advances
Verified
Journal Article
Closed access
PDF file
HXHongbo Xie
Hongbo Xie
HWHaixia Wen
Haixia Wen
MQMingze Qin
Mingze Qin
JXJie Xia
Jie Xia
DZDenan Zhang
Denan Zhang
Xiujie ChenXiujie Chen
Xiujie Chen
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder that affects the elderly. Despite the devastating effects of this disease, therapeutic methods for the treatment of AD remain limited, as many factors contribute to its etiology. In recent decades, many small molecules and bioproducts have been developed for the treatment of AD; however, there are still no drugs that produce efficient disease-modifying effects. Drug repositioning is an alternative methodology for drug discovery because many effective drugs act via the modulation of multiple targets, and this ‘poly-pharmacology’ can be a therapeutic requirement for complex diseases. The multifactorial nature of AD strongly supports the rationale for a drug design strategy centered on drug repositioning. In this study, a computational pipeline based on ligand–protein inverse docking and gene expression data mining were adopted to explore potential drugs for the treatment of AD. We performed a virtual screening of 1553 FDA-approved drugs on seven major AD drug targets. Several drugs showed extremely high binding free energies for the seven targets. Furthermore, gene expression data represent a very rich alternative resource for inferring non-obvious relationships between drugs and genes. The gene expression profiles in response to the identified drugs support the docking results and offer a plausible perspective on the pathways associated with protein responses to drug binding in AD patients. The results have led to the discovery of droperidol, glimepiride, risperidone and other FDA-approved drugs as potential multi-target candidates for the treatment of AD.

13 June 2024 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JCJunpeng Cheng
Junpeng Cheng
MXMeizhu Xiao
Meizhu Xiao
QMQingkang Meng
Qingkang Meng
MZMin Zhang
Min Zhang
DZDenan Zhang
Denan Zhang
HXHongbo Xie
Hongbo Xie
Background: Non-small cell lung cancer (NSCLC) is a prevalent and heterogeneous disease with significant genomic variations between the early and advanced stages. The identification of key genes and pathways driving NSCLC tumor progression is critical for improving the diagnosis and treatment outcomes of this disease. Methods: In this study, we conducted single-cell transcriptome analysis on 93,406 cells from 22 NSCLC patients to characterize malignant NSCLC cancer cells. Utilizing cNMF, we classified these cells into distinct modules, thus identifying the diverse molecular profiles within NSCLC. Through pseudotime analysis, we delineated temporal gene expression changes during NSCLC evolution, thus demonstrating genes associated with disease progression. Using the XGBoost model, we assessed the significance of these genes in the pseudotime trajectory. Our findings were validated by using transcriptome sequencing data from The Cancer Genome Atlas (TCGA), supplemented via LASSO regression to refine the selection of characteristic genes. Subsequently, we established a risk score model based on these genes, thus providing a potential tool for cancer risk assessment and personalized treatment strategies. Results: We used cNMF to classify malignant NSCLC cells into three functional modules, including the metabolic reprogramming module, cell cycle module, and cell stemness module, which can be used for the functional classification of malignant tumor cells in NSCLC. These findings also indicate that metabolism, the cell cycle, and tumor stemness play important driving roles in the malignant evolution of NSCLC. We integrated cNMF and XGBoost to select marker genes that are indicative of both early and advanced NSCLC stages. The expression of genes such as CHCHD2, GAPDH, and CD24 was strongly correlated with the malignant evolution of NSCLC at the single-cell data level. These genes have been validated via histological data. The risk score model that we established (represented by eight genes) was ultimately validated with GEO data. Conclusion: In summary, our study contributes to the identification of temporal heterogeneous biomarkers in NSCLC, thus offering insights into disease progression mechanisms and potential therapeutic targets. The developed workflow demonstrates promise for future applications in clinical practice.

26 December 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
DZDenan Zhang
Denan Zhang
LLLei Liu
Lei Liu
LPLin Pang
Lin Pang
QJQing Jin
Qing Jin
KKKehui Ke
Kehui Ke
Xiujie ChenXiujie Chen
Xiujie Chen

30 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
QMQingkang Meng
Qingkang Meng
FWFeng Wu
Feng Wu
GLGuoqi Li
Guoqi Li
FXFei Xu
Fei Xu
LLLei Liu
Lei Liu
Xiujie ChenXiujie Chen
Xiujie Chen
At present, most patients with oral squamous cell carcinoma (OSCC) are in the middle or advanced stages at the time of diagnosis. Advanced OSCC patients have a poor prognosis after traditional therapy, and the complex heterogeneity of OSCC has been proven to be one of the main reasons. Single-cell sequencing technology provides a powerful tool for dissecting the heterogeneity of cancer. However, most of the current studies at the single-cell level are static, while the development of cancer is a dynamic process. Thus, understanding the development of cancer from a dynamic perspective and formulating corresponding therapeutic measures for achieving precise treatment are highly necessary, and this is also one of the main study directions in the field of oncology. In this study, we combined the static and dynamic analysis methods based on single-cell RNA-Seq data to comprehensively dissect the complex heterogeneity and evolutionary process of OSCC. Subsequently, for clinical practice, we revealed the association between cancer heterogeneity and the prognosis of patients. More importantly, we pioneered the concept of pseudo-time score of patients, and we quantified the levels of heterogeneity based on the dynamic development process to evaluate the relationship between the score and the survival status at the same stage, finding that it is closely related to the prognostic status. The pseudo-time score of patients could not only reflect the tumor status of patients but also be used as an indicator of the effects of drugs on the patients so that the medication strategy can be adjusted on time. Finally, we identified candidate drugs and proposed precision medication strategies to control the condition of OSCC in two respects: treatment and blocking.